ANCO Resources Related to Drug Shortages
The Association of Northern California Oncologists (ANCO) is monitoring the drug shortage crisis and is committed to providing members with the best possible information to stay informed. The medical community continues to experience shortages of critical drugs used to treat a variety of conditions. Currently, more than a dozen oncology drugs are on the FDA’s shortage list. Resources provided below:
- Current Supply Chain Disruption
- ANCO and MOASC Statement on Cancer Care Drug Shortage
- Articles
- Statements Addressing Ongoing Chemotherapy Shortages
- ASCO Resources Related to Drug Shortages
Current Supply Chain Disruption
This is the status of the current supply chain disruption, October 9, 2024
The impacts of Hurricane Helene have led to the temporary supply disruption at the Baxter facility in Marion, North Carolina. The Baxter facility provides a significant portion of IV solutions, irrigation fluids, and peritoneal solutions to the U.S. medical system. There are currently shortages of normal saline IV fluids, normal saline irrigation fluid, sterile water irrigation, and dextrose 5% IV fluids that pre-date Hurricane Helene. The hurricane-related supply disruption at the Baxter facility will likely lead to further constraints for IV fluids. However, compounding of drugs on the U.S. Food & Drug Administration (FDA) shortage list can be done in accordance with current requirements to help alleviate shortages [see Compounding when Drugs are on FDA’s Drug Shortages List | FDA]. In the coming weeks, supply may continue to be constrained, and we understand that certain products are on allocation; however, Baxter reported that they have resumed shipments to hospitals and dialysis providers and patients after the temporary hold last week, based on allocations as previously communicated. The inventory will be used to support current allocations in the short term, and they note that several of their global plants are scaling and ramping production to help meet U.S. needs. Other producers are expected to be able to continue to fulfill domestic orders within their allocation.
Articles
ANCO and MOASC STATEMENT ON CANCER CARE DRUG SHORTAGE
Read ANCO and MOASC’s statement on the cancer care drug shortage.
Articles
https://www.cnbc.com/2023/06/01/cancer-drug-shortage-fda-mulls-overseas-chemotherapy-imports.html
https://anco.org/site/wp-content/uploads/2023/06/TCL49-22-June-2-23.pdf
Statements Addressing Ongoing Chemotherapy Shortages
ANCO & MOASC – ANCO and MOASC Statement on Cancer Care Drug Shortage
ASCO – https://old-prod.asco.org/practice-patients/practice-support/drug-shortages
NCCN – https://www.nccn.org/home/news/newsdetails?NewsId=3970
SGO – https://www.sgo.org/news/drugshortage/
FDA Allows More Cancer Drug Imports From China as US Faces Shortages
US regulators are allowing imports of additional supplies of a cancer drug from China amid a nationwide shortage that has forced doctors to ration care, putting patients’ lives at risk. The FDA has allowed distribution of 10 more lots of cisplatin, an essential chemotherapy drug, from Qilu Pharmaceutical Co., an agency spokesperson said Monday.
Learn More
“My ANCO membership and board involvement have been invaluable in enabling me to connect with colleagues beyond my sphere at Stanford. I have had the opportunity to interact with physicians at UCSF, UC Davis, the Permanente Medical Group and with numerous private practices. My participation in the enlightening Multidisciplinary Management of Cancers Meeting has enriched my career and connections with oncologists in Northern California.”
A. Dimitrios Colevas, M.D.
Professor of Medicine, Stanford University